Project Oncology®

One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay tests, could change all of that, as Dr. Tony Hu explains.

Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.

Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.

Short for hyperthermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC.

For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.

Short for hyperthermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC.

For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment.

US-32345 Last Updated 12/19

At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer.

US-32360 Last Updated 12/19

Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.

When compared to traditional x-ray radiation therapy, proton beam therapy is a more targeted form of therapy that offers a lower dose of radiation to impacted organs and fewer side effects and complications, which explains why its being recommended as a treatment option more and more. But what are some of the other benefits—and challenges—of proton beam therapy? That’s what Drs. Anita Mahajan and Robert Foote are here to discuss.

For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.

About a third of the 55,000 Americans diagnosed with pancreatic cancer each year were considered inoperable due to the tumor growing outside the pancreas. But now, that conventional wisdom is being challenged with the release of data from a recent study, as Dr. Chee-Chee Stucky, a surgical oncologist from Mayo Clinic, explains.

For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

As new evidence continues to be published and presented at scientific conferences, oncologists are finding it more difficult to stay on top of new information. That’s why Drs. Eileen O'Reilly and Paul Oberstein are here to review selected abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting… but the catch is that they only have 3 minutes to cover each update in this clinical countdown discussion. Can they beat the clock?

As new evidence continues to be published and presented at scientific conferences, oncologists are finding it more difficult to stay on top of new information. That’s why Drs. Eileen O'Reilly and Paul Oberstein are here to review selected abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting… but the catch is that they only have 3 minutes to cover each update in this clinical countdown discussion. Can they beat the clock?